Artículos de revistas: "Antibody treatment"

1

Sasaki, Shigeru, Yasuhisa Shinomura y Kozo Imai. "Antibody treatment". Drug Delivery System 30, n.º 1 (2015): 16–24. http://dx.doi.org/10.2745/dds.30.16.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

2

Jolobe, O. M. "Monoclonal antibody treatment". BMJ 340, apr01 2 (1 de abril de 2010): c1850. http://dx.doi.org/10.1136/bmj.c1850.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

3

Litzman, Jiří. "Treatment of antibody immunodeficiency". Vnitřní lékařství 65, n.º 2 (1 de febrero de 2019): 126–30. http://dx.doi.org/10.36290/vnl.2019.025.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

4

Espinoza, LR. "Antiphospholipid Antibody Syndrome: Treatment". Lupus 5, n.º 5 (octubre de 1996): 456–57. http://dx.doi.org/10.1177/096120339600500525.

Texto completo

Resumen

Of the many clinical manifestations seen in the antiphospholipid antibody syndrome (APAS), two deserve major therapeutic consideration: recurrent fetal loss and vascular thromboses. Treatment of these two major complications remain empirical, although recent studies appear to indicate the beneficial use of multiple therapeutic options including low dose aspirin, alone or in combination with a moderate amount of prednisone, heparin and intravenous gammaglobulin for the prevention of fetal loss, and longterm anticoagulation with maintenance of an international normalized ratio (INR) of 3 to 4 as an effective measure in the prevention of vascular thrombosis. The use of interleukin-3 in animal models of the syndrome has been shown to be effective in the prevention of fetal loss, and this therapeutic modality appears promising, particularly because of its recognized low frequency of side effects in therapeutic trials in humans.

Los estilos APA, Harvard, Vancouver, ISO, etc.

5

Mehdi, Ali A., Imad Uthman y Munther Khamashta. "Treatment of antiphospholipid antibody syndrome". International Journal of Clinical Rheumatology 5, n.º 2 (abril de 2010): 241–54. http://dx.doi.org/10.2217/ijr.10.8.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

6

Gibbons, W. "Antibody Treatment Joins AIDS Battle". Science News 139, n.º 4 (26 de enero de 1991): 55. http://dx.doi.org/10.2307/3975553.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

7

Liddle, Rachel. "Antibody treatment for ovarian cancer". Lancet Oncology 8, n.º 8 (agosto de 2007): 676. http://dx.doi.org/10.1016/s1470-2045(07)70229-2.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

8

Vexler, Vladimir y Jacky Woo. "Antibody treatment of ulcerative colitis". Drug Discovery Today: Therapeutic Strategies 3, n.º 3 (septiembre de 2006): 353–60. http://dx.doi.org/10.1016/j.ddstr.2006.07.002.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

9

Wahl, Denis y Veronique Regnault. "Treatment of Antiphospholipid Antibody Syndrome". JAMA 296, n.º 1 (5 de julio de 2006): 42. http://dx.doi.org/10.1001/jama.296.1.42.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

10

Gardulf, Ann. "Immunoglobulin Treatment for Primary Antibody Deficiencies". BioDrugs 21, n.º 2 (2007): 105–16. http://dx.doi.org/10.2165/00063030-200721020-00005.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

11

Carter, Thomas, Paul Mulholland y Kerry Chester. "Antibody-targeted nanoparticles for cancer treatment". Immunotherapy 8, n.º 8 (julio de 2016): 941–58. http://dx.doi.org/10.2217/imt.16.11.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

12

Stronkhorst, A., G. N. J. Tytgat y S. J. H. Van Deventer. "CD4 Antibody Treatment in Crohn's Disease". Scandinavian Journal of Gastroenterology 27, sup194 (enero de 1992): 61–65. http://dx.doi.org/10.3109/00365529209096029.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

13

Slomski, Anita. "Monoclonal Antibody Overcomes Migraine Treatment Failure". JAMA 328, n.º 8 (23 de agosto de 2022): 700. http://dx.doi.org/10.1001/jama.2022.13588.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

14

Gao, Jie, Huaiwen Chen, Hao Song, Xiao Su, Fangfang Niu, Wei Li, Bohua Li, Jianxin Dai, Hao Wang y Yajun Guo. "Antibody-Targeted Immunoliposomes for Cancer Treatment". Mini-Reviews in Medicinal Chemistry 13, n.º 14 (31 de diciembre de 2013): 2026–35. http://dx.doi.org/10.2174/1389557513666131119202717.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

15

Sinclair, Leslie. "Antibody Shows Promise As Alzheimer’s Treatment". Psychiatric News 47, n.º 11 (junio de 2012): 23a. http://dx.doi.org/10.1176/pn.47.11.psychnews_47_11_23-a.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

16

Popova, E. V. "MONOCLONAL ANTIBODY FOR MULTIPLE SCLEROSIS TREATMENT". Medical Council, n.º 10 (1 de enero de 2017): 65–68. http://dx.doi.org/10.21518/2079-701x-2017-10-65-68.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

17

Badger, Christopher C., Claudio Anasetti, Jeff Davis y Irwin D. Bernstein. "Treatment of Malignancy with Unmodified Antibody". Pathology and Immunopathology Research 6, n.º 5-6 (1987): 419–34. http://dx.doi.org/10.1159/000157067.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

18

PULLYBLANK, A. M. y J. R. T. MONSON. "Monoclonal antibody treatment of colorectal cancer". BJS 84, n.º 11 (noviembre de 1997): 1511–17. http://dx.doi.org/10.1111/j.1365-2168.1997.00560.x.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

19

Lambert, John M. y Anna Berkenblit. "Antibody–Drug Conjugates for Cancer Treatment". Annual Review of Medicine 69, n.º 1 (29 de enero de 2018): 191–207. http://dx.doi.org/10.1146/annurev-med-061516-121357.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

20

Gould, Paula. "Monoclonal antibody aids colorectal-cancer treatment". Lancet Oncology 7, n.º 5 (mayo de 2006): 370. http://dx.doi.org/10.1016/s1470-2045(06)70681-7.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

21

Sullivan, Timothy J., David Grimes y Ian Bunce. "Monoclonal Antibody Treatment of Orbital Lymphoma". Ophthalmic Plastic & Reconstructive Surgery 20, n.º 2 (marzo de 2004): 103–6. http://dx.doi.org/10.1097/01.iop.0000115594.98470.ac.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

22

Nicolas, J. F., N. Chamchick, J. Thivolet, J. Wijdenes, P. Morel y J. P. Revillard. "CD4 antibody treatment of severe psoriasis". Lancet 338, n.º 8762 (agosto de 1991): 321. http://dx.doi.org/10.1016/0140-6736(91)90465-2.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

23

Walko, Christine M. y Howard (Jack) West. "Antibody Drug Conjugates for Cancer Treatment". JAMA Oncology 5, n.º 11 (1 de noviembre de 2019): 1648. http://dx.doi.org/10.1001/jamaoncol.2019.3552.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

24

Baldwin, R. W. y V. S. Byers. "Monoclonal antibody immunoconjugates for cancer treatment". Current Opinion in Immunology 1, n.º 5 (junio de 1989): 891–94. http://dx.doi.org/10.1016/0952-7915(89)90066-6.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

25

Wu, Christopher y Kenneth Kalunian. "Treatment of the antiphospholipid antibody syndrome". Current Rheumatology Reports 6, n.º 6 (diciembre de 2004): 463–68. http://dx.doi.org/10.1007/s11926-004-0026-z.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

26

Pullyblank, A. M. y J. R. T. Monson. "Monoclonal antibody treatment of colorectal cancer". British Journal of Surgery 84, n.º 11 (noviembre de 1997): 1511–17. http://dx.doi.org/10.1002/bjs.1800841106.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

27

Lim, Wendy, Mark Crowther y John Eikelboom. "Treatment of Antiphospholipid Antibody Syndrome—Reply". JAMA 296, n.º 1 (5 de julio de 2006): 42. http://dx.doi.org/10.1001/jama.296.1.43-a.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

28

Maarschalk-Ellerbroek, L. J., I. M. Hoepelman y P. M. Ellerbroek. "Immunoglobulin treatment in primary antibody deficiency". International Journal of Antimicrobial Agents 37, n.º 5 (mayo de 2011): 396–404. http://dx.doi.org/10.1016/j.ijantimicag.2010.11.027.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

29

Panda, Manasi. "Rabies-Monoclonal Antibody - A Perspective". Journal of Communicable Diseases 54, n.º 03 (30 de septiembre de 2022): 22–26. http://dx.doi.org/10.24321/0019.5138.202285.

Texto completo

Resumen

Rabies is an acute viral zoonotic disease that affects the central nervous system (CNS) of all warm-blooded animals, including mammals. Research studies and experience from across the world have demonstrated that appropriate administration of a combination of (a) local wound treatment, (b) anti-rabies vaccination and (c) passive immunization have proved to be quite effective in preventing the occurrence of rabies. As far as passive immunization is concerned, polyclonal plasma-derived rabies immunoglobulins (RIG) pose a number of limitations with scarce supply, high cost, etc. amongst many others. On the contrary Rabies Monoclonal Antibodies (R-mAb) are much cheaper, permit longer-term storage, etc. and hence could offer a more standardized, accessible, affordable and equally efficacious and safer alternative to RIG. Accordingly, this article has tried to throw light on the transition from RIG to monoclonal antibody-based Post Exposure Prophylaxis (PEP) which has been recommended by the WHO strongly. The advantages, limitations and future scope of R-mAb have been discussed at length to give a comprehensive idea about this novel invention in the field of medicine.

Los estilos APA, Harvard, Vancouver, ISO, etc.

30

Chiu, Daniel, John Rhee y L. Nicolas Gonzalez Castro. "Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes". Antibodies 12, n.º 3 (31 de julio de 2023): 50. http://dx.doi.org/10.3390/antib12030050.

Texto completo

Resumen

Paraneoplastic antibody syndromes result from the anti-tumor antibody response against normal antigens ectopically expressed by tumor cells. Although this antibody response plays an important role in helping clear a nascent or established tumor, the engagement of antigens expressed in healthy tissues can lead to complex clinical syndromes with challenging diagnosis and management. The majority of known paraneoplastic antibody syndromes have been found to affect the central and peripheral nervous system. The present review provides an update on the pathophysiology of paraneoplastic neurologic syndromes, as well as recommendations for their diagnosis and treatment.

Los estilos APA, Harvard, Vancouver, ISO, etc.

31

Yano, Yusuke, Nobuhito Hamano, Kenshin Haruta, Tomomi Kobayashi, Masahiro Sato, Yamato Kikkawa, Yoko Endo-Takahashi et al. "Development of an Antibody Delivery Method for Cancer Treatment by Combining Ultrasound with Therapeutic Antibody-Modified Nanobubbles Using Fc-Binding Polypeptide". Pharmaceutics 15, n.º 1 (30 de diciembre de 2022): 130. http://dx.doi.org/10.3390/pharmaceutics15010130.

Texto completo

Resumen

A key challenge in treating solid tumors is that the tumor microenvironment often inhibits the penetration of therapeutic antibodies into the tumor, leading to reduced therapeutic efficiency. It has been reported that the combination of ultrasound-responsive micro/nanobubble and therapeutic ultrasound (TUS) enhances the tissue permeability and increases the efficiency of delivery of macromolecular drugs to target tissues. In this study, to facilitate efficient therapeutic antibody delivery to tumors using this combination system, we developed therapeutic antibody-modified nanobubble (NBs) using an Fc-binding polypeptide that can quickly load antibodies to nanocarriers; since the polypeptide was derived from Protein G. TUS exposure to this Herceptin®-modified NBs (Her-NBs) was followed by evaluation of the antibody’s own ADCC activity, resulting the retained activity. Moreover, the utility of combining therapeutic antibody-modified NBs and TUS exposure as an antibody delivery system for cancer therapy was assessed in vivo. The Her-NBs + TUS group had a higher inhibitory effect than the Herceptin and Her-NBs groups. Overall, these results suggest that the combination of therapeutic antibody-modified NBs and TUS exposure can enable efficient antibody drug delivery to tumors, while retaining the original antibody activity. Hence, this system has the potential to maximize the therapeutic effects in antibody therapy for solid cancers.

Los estilos APA, Harvard, Vancouver, ISO, etc.

32

Hosoya, Hitomi y Surbhi Sidana. "Antibody-Based Treatment Approaches in Multiple Myeloma". Current Hematologic Malignancy Reports 16, n.º 2 (17 de marzo de 2021): 183–91. http://dx.doi.org/10.1007/s11899-021-00624-6.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

33

Gao, Jie, Si-Shen Feng y Yajun Guo. "Antibody engineering promotes nanomedicine for cancer treatment". Nanomedicine 5, n.º 8 (octubre de 2010): 1141–45. http://dx.doi.org/10.2217/nnm.10.94.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

34

Scherrmann, Jean-Michel. "Antibody Treatment of Toxin Poisoning Recent Advances". Journal of Toxicology: Clinical Toxicology 32, n.º 4 (enero de 1994): 363–75. http://dx.doi.org/10.3109/15563659409011037.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

35

White, Christine A., Robin L. Weaver y Antonio J. Grillo-López. "Antibody-Targeted Immunotherapy for Treatment of Malignancy". Annual Review of Medicine 52, n.º 1 (febrero de 2001): 125–45. http://dx.doi.org/10.1146/annurev.med.52.1.125.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

36

Pietersz, Geoffrey A. y Ian F. C. McKenzie. "Antibody Conjugates for the Treatment of Cancer". Immunological Reviews 129, n.º 1 (octubre de 1992): 57–80. http://dx.doi.org/10.1111/j.1600-065x.1992.tb01419.x.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

37

Makawita, Shalini y Funda Meric-Bernstam. "Antibody-Drug Conjugates: Patient and Treatment Selection". American Society of Clinical Oncology Educational Book, n.º 40 (mayo de 2020): 105–14. http://dx.doi.org/10.1200/edbk_280775.

Texto completo

Resumen

Antibody-drug conjugates (ADCs) are a promising drug platform designed to enhance the therapeutic index and minimize the toxicity of anticancer agents. ADCs have experienced substantial progress and technological growth over the past decades; however, several challenges to patient selection and treatment remain. Methods to optimally capture all patients who may benefit from a particular ADC are still largely unknown. Although target antigen expression remains a biomarker for patient selection, the impact of intratumor heterogeneity on antigen expression, as well as the dynamic changes in expression with treatment and disease progression, are important considerations in patient selection. Better understanding of these factors, as well as minimum levels of target antigen expression required to achieve therapeutic efficacy, will enable further optimization of selection strategies. Other important considerations include understanding mechanisms of primary and acquired resistance to ADCs. Ongoing efforts in the design of its constituent parts to possess the intrinsic ability to overcome these mechanisms, including use of the “bystander effect” to enhance efficacy in heterogeneous or low target antigen-expressing tumors, as well as modulation of the chemical and immunophenotypic properties of antibodies and linker molecules to improve payload sensitivity and therapeutic efficacy, are under way. These strategies may also lead to improved safety profiles. Similarly, combination strategies using ADCs with other cytotoxic or immunomodulatory agents are also under development. Great strides have been made in ADC technology. With further refinements, this therapeutic modality has the potential to make an important clinical impact on a wider range of tumor types.

Los estilos APA, Harvard, Vancouver, ISO, etc.

38

van Deventer, S. J. H. "Anti-TNF antibody treatment of Crohn's disease". Annals of the Rheumatic Diseases 58, Supplement 1 (1 de noviembre de 1999): i114—i120. http://dx.doi.org/10.1136/ard.58.2008.i114.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

39

Sattui, Sebastian E. y Robert F. Spiera. "Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis". Rheumatic Disease Clinics of North America 45, n.º 3 (agosto de 2019): 379–98. http://dx.doi.org/10.1016/j.rdc.2019.04.006.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

40

Gilbert, EdwardM, JohnB O'Connell, M. Elizabeth Hammond, DaleG Renlund, FredrickS Watson y MichaelR Bristow. "TREATMENT OF MYOCARDITIS WITH OKT3 MONOCLONAL ANTIBODY". Lancet 331, n.º 8588 (abril de 1988): 759. http://dx.doi.org/10.1016/s0140-6736(88)91555-3.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

41

SKERRETT, S. "Antibody treatment of lower respiratory tract infections1". Seminars in Respiratory Infections 16, n.º 1 (marzo de 2001): 67–75. http://dx.doi.org/10.1053/srin.2001.22730.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

42

Singh, Neeraj, John Pirsch y Millie Samaniego. "Antibody-mediated rejection: treatment alternatives and outcomes". Transplantation Reviews 23, n.º 1 (enero de 2009): 34–46. http://dx.doi.org/10.1016/j.trre.2008.08.004.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

43

Ribas, Antoni, John M. Kirkwood y Keith T. Flaherty. "Anti-PD-1 antibody treatment for melanoma". Lancet Oncology 19, n.º 5 (mayo de 2018): e219. http://dx.doi.org/10.1016/s1470-2045(18)30202-x.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

44

Cornely, O. A., C. N. Heidecke y M. Karthaus. "Opportunistic infections (OI) following monoclonal antibody treatment". Journal of Clinical Oncology 23, n.º 16_suppl (junio de 2005): 2562. http://dx.doi.org/10.1200/jco.2005.23.16_suppl.2562.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

45

Mulford, Deborah A. y Joseph G. Jurcic. "Antibody-based treatment of acute myeloid leukaemia". Expert Opinion on Biological Therapy 4, n.º 1 (enero de 2004): 95–105. http://dx.doi.org/10.1517/14712598.4.1.95.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

46

Garfin, Phillip M. y Eric J. Feldman. "Antibody-Based Treatment of Acute Myeloid Leukemia". Current Hematologic Malignancy Reports 11, n.º 6 (12 de octubre de 2016): 545–52. http://dx.doi.org/10.1007/s11899-016-0349-7.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

47

Bosch, Xavier, Antonio Guilabert, Gerard Espinosa y Eduard Mirapeix. "Treatment of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis". JAMA 298, n.º 6 (8 de agosto de 2007): 655. http://dx.doi.org/10.1001/jama.298.6.655.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

48

Lown, John. "Enzyme treatment of platelets for antibody detection". Transfusion 43, n.º 6 (21 de mayo de 2003): 835. http://dx.doi.org/10.1046/j.1537-2995.2003.00415.x.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

49

Ross, Ryan D., Lindsey H. Edwards, Alvin S. Acerbo, Michael S. Ominsky, Amarjit S. Virdi, Kotaro Sena, Lisa M. Miller y D. Rick Sumner. "Bone Matrix Quality After Sclerostin Antibody Treatment". Journal of Bone and Mineral Research 29, n.º 7 (25 de junio de 2014): 1597–607. http://dx.doi.org/10.1002/jbmr.2188.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

50

Han, Yizhao, Zhuojun Liu, Jia Liu, Weiqi Yan, Yuanshi Xia, Shuhua Yue y Jian Yu. "Antibody-Based Immunotherapeutic Strategies for the Treatment of Hematological Malignancies". BioMed Research International 2020 (18 de septiembre de 2020): 1–8. http://dx.doi.org/10.1155/2020/4956946.

Texto completo

Resumen

As the most common type of cancer in the world, hematological malignancies (HM) account for 10% of all annual cancer deaths and have attracted more attention. Conventional treatments, such as chemotherapy, radiotherapy, and hematopoietic stem cell transplantation (HSCT), could relieve patients suffering HM. However, serious side effects and high costs bring patients both physical complaints and mental pressure. Recently, compared with conventional therapeutic strategies for HM patients, antibody-based immunotherapies, including cancer vaccines, oncolytic virus therapies, monoclonal antibody treatments, and CAR-T cell therapies, have displayed longer survival time and fewer adverse reactions, even though specific efficacy and safety of these antibody-based immunotherapies still need to be evaluated and improved. This review summarized the advantages of antibody-based immunotherapies over conventional treatments, as well as its existing difficulties and solutions, thereby enhancing the understanding and applications of antibody-based immunotherapies in HM treatment.

Los estilos APA, Harvard, Vancouver, ISO, etc.

Artículos de revistas sobre el tema "Antibody treatment"

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros